Voluntary Accreditation of Immune Effector Cell Programs
|
|
- Erika Newton
- 6 years ago
- Views:
Transcription
1 Voluntary Accreditation of Immune Effector Cell Programs From Clinical Trials to Licensure and Beyond Phyllis I. Warkentin, MD September 6, 2017
2 Presentation Outline FACT Standards and Accreditation Program Immune Effector Cell Standards and Accreditation Voluntary FACT Accreditation can Help the Field
3 FACT Background Founded in 1996 by ASBMT (clinicians, scientists) and ISCT (laboratory scientists) to be their standards setting and accreditation arm to address: Perceived need for minimal standards across the fields of hematology/oncology and stem cell transplantation Mitigate perceived burden of regulatory oversight Develop accreditation process encompassing clinical practices, cell collection, and laboratory services Partner: JACIE to foster international collaboration Partner: NetCord to expand standards for CBB 1998 Partner: CIBMTR to improve data management
4 FACT s Beginnings
5 FACT Mission Promote quality patient care and laboratory services Improve transplant / treatment outcomes Foster continued development of cellular therapies Pursued through three core services Standards Accreditation Education
6 FACT Standards Developed by consensus of experts in the field Clinicians, scientists, technologists, nurses, pharmacists, quality experts, others Based on published medical literature whenever available Public comment; legal and regulatory review; revision: Board approval Minimal requirements; not intended to establish best practices Not prescriptive; allow flexibility; many ways to comply All Standards require: Comprehensive Quality Management program Assessment of relevant end points variable depending on phase of product Safety; efficacy; clinical patient outcomes Compliance with regulations of competent authorities
7 FACT Accreditation Program Voluntary Programs hold themselves to a higher standard for the benefit of patients Based on compliance with Standards Peer-driven Inspectors: volunteer professionals, active in the field; experts in areas they inspect Inspectors teach, coach, mentor, and learn from inspections Consistent; staff coordinators; Accreditation Committee review International Accredited 182 cellular therapy programs in 7 countries; 224 facilities Accredited 57 cord blood banks in 25 countries and expanding
8 FACT Educational Activities Workshops, Webinars, On-demand Webcasts Inspector Training; Applicant Preparation Quality Management Series Joint online events with related organizations (NetCord, ASGCT) Back to Basics: Handling Car-T Cell Products Cytokine Release Syndrome Ask a Peer and Ask FACT Accreditation Manual with Guidance Explanation, Evidence, Examples Allied Learning Center (ASBMT, ISCT, etc.) Newsletters
9 DEVELOPMENT OF IMMUNE EFFECTOR CELL (IEC) STANDARDS AND ACCREDITATION
10 What are Immune Effector Cells? Broadly defined as cells that are capable of modulating, eliciting, or mitigating an immune response for therapeutic effect Common products Chimeric Antigen Receptor T Cells (CAR-T) Chimeric Antigen Receptor NK Cells (CAR-NK) Cytotoxic T lymphocytes active against viruses or tumor Tumor Infiltrating Lymphocytes (TIL) Therapeutic dendritic cell based vaccines Not included: DLI (unmanipulated donor T Cells) T cells B cells Natural Killer cells Dendritic cells Mesenchymal Stromal cells
11 Why Standards for Immune Effector Cells? FACT-accredited transplant programs Participation in immune effector cell trials Unique challenges: logistics of delivery and toxicities, particularly Car-T therapies Non-transplant units using immuneeffector cells Lack of clarity: accreditation Regulators Responsibility for approving only safe and effective products for licensure Interest in field s ability to handle toxicities Patient Safety, Outcomes, and Access Drug manufacturers Investment in controlled, safe clinical trials Ensure continued proper handling and use of products when commercially available outside of research study environment Payers Anticipation of drug licensure requests for reimbursement Expectation of good outcomes for covered services; criteria for centers of excellence
12 FACT Immune Effector Cell Task Force Helen Heslop, MD Chair (ASGCT representative) Baylor College of Medicine Houston, TX Michael Lill, MD Vice-Chair Cedars-Sinai Medical Center Los Angeles, CA Elizabeth Shpall, MD Vice-Chair MD Anderson Cancer Center Houston, TX Carlos Bachier, MD Sarah Cannon BMT Program Nashville, TN Kevin Curran, MD Memorial Sloan-Kettering Cancer Center New York, NY David Maloney, MD, PhD Fred Hutchinson Cancer Research Center Seattle, WA Marcela Maus, MD, PhD (SITC representative) Dana Farber/Harvard Cancer Center Boston, MA Philip McCarthy, MD Roswell Park Cancer Institute Buffalo, NY Sarah Nikiforow, MD, PhD Dana Farber Cancer Institute Boston, MA Jae Park, MD Memorial Sloan-Kettering Cancer Center New York, NY David Porter, MD Penn Medicine Philadelphia, PA Phyllis Warkentin, MD University of Nebraska Medical Center & FACT CMO Omaha, NE
13 Task Force Accomplishments Reviewed FACT Common Standards for Cellular Therapies Conclusions: FACT Common Standards are generic; applicable to immune effector cell products Some Standards unique to immune effector cell can be delineated Specific unique Standards should apply to IECs regardless of clinical setting Standards should be packaged in a format easily accessible to users regardless of clinical care structure Standards focus on clinical requirements most specific; most variable structures FACT IEC Standards focus on processes, documentation, and oversight, not on scientific validity, vector design, or manufacturing details for any product
14 FACT Standards FACT Standards for Immune Effector Cells, First Edition Common Standards + Immune Effector Cell-Specific Standards Apply to programs only performing immune effector cell therapy FACT Common Standards for Cellular Therapies, First Edition Standards common to any type of cellular therapy Requirements within included in other sets of Standards Associated accreditation applies to programs not performing hematopoietic cell transplantation or immune effector cell therapy FACT-JACIE International Standards for Hematopoietic Cellular Therapy Product Collection, Processing, and Administration, Edition 6.1 HCT Standards + Immune Effector Cell-Specific Standards Apply to transplant units that may or may not administer immune effector cells
15 Organization of the Immune Effector Cells: Accommodating Different Models of Care Common Standards Clinical departments separate from transplant (e.g., leukemia service) Immune Effector Cell Standards Hematopoietic Cell Therapy Standards Hematopoietic Stem Cell Transplant Programs
16 Scope of Immune Effector Cell Standards Processes not science Donor selection and management, collection, labeling, transportation, preparation for administration, administration, management of adverse events, evaluation of clinical outcome Quality Management (QM) program Establishes, maintains, monitors, and implements improvements Includes written SOPs, personnel training and competency, document and record control, GDP, documentation of adverse events, clinical follow up Manufacturing as it occurs under IND in accredited laboratories Control of processes, equipment, supplies, reagents, facilities, personnel Focus: chain of custody, labeling, transportation, storage Education
17 Standards Specific to Immune Effector Cells Specific IEC Standards are focused on four areas: Third-party manufacturers and importance of identity Cytokine release syndrome and other complications Coordination and education among different departments Data management
18 Third-Party Manufacturers - I The level of participation of the clinical service in manufacturing an immune effector cell product varies; location varies Regardless of where the product is collected or manufactured, responsibilities must be clearly defined: Ensure and verify chain of custody through multiple handoffs and relabeling from cell collection product administration Programs should have documentation of the quality of the manufacturing laboratory (appropriate regulatory oversight; acceptable standards): A quality audit or report of a quality audit performed by the holder of the Investigational New Drug (IND) application Certificate of Accreditation Licensure
19 Third-Party Manufacturers - II If cellular therapy products are received directly by the Clinical Program from a third-party manufacturer, the following responsibilities shall be defined at a minimum: Chain of custody of cellular therapy products From donor at collection, through transport/shipping, to recipient at clinical center Clinical program must be confident this is the product intended for this recipient Cellular therapy product storage [secure; temperature] Verification of cellular therapy product identity Management of adverse events
20 Labeling Challenges Products rely on labeling and identifiers to confirm identity Many products are patient-specific autologous or matched allogeneic donors No real time serological / antigen testing to confirm identity of product to a specific patient Various labeling formats and practices for third party manufactured products Reluctance to use patient identifiers de-identifying / relabeling Frequent use of study numbers not truly unique ; near misses reported IEC Standards require unique product identification; process controls HCT Standards: ISBT128 labeling Recognized by WHO as the global standard for identification and coding of medical products of human origin Unique product identification allows traceability collection administration Does not preclude use of other identifiers, product names, study numbers 667 cellular therapy facilities in 62 countries registered to use ISBT128
21 Cytokine Release Syndrome - I Procedures shall include detection and management of immune effector cellular therapy complications, including cytokine release syndrome and CNS disease Pharmacies shall have access to formularies adequate to treat cytokine release syndrome and other expected complications of immune effector cell administration Physician, Advance Practice Provider/Professional, and Nurse training and competency must include care interventions to manage complications including: Cytokine release syndrome - Renal and hepatic failure Cardiac dysfunction - Disseminated intravascular coagulation Respiratory distress - Anaphylaxis Neurologic toxicity
22 Cytokine Release Syndrome II STANDARDS: Clinical Program written guidelines for management of complications [including cytokine-blocking agents and corticosteroids] Regular assessment of the recipient to detect complications, including CRS and neurologic dysfunction Process for rapid escalation of care, increased intensity of monitoring, and relevant workup Timely communication to clinical staff, ICUs, ERs, and pharmacies ASSESSMENTS: Example situation to assess: how to manage CRS after the hospital pharmacy closes? Potential sources of information: document reviews, record reviews, personnel interviews, role playing
23 Outcome Analysis and Data Management Review outcome analysis and product efficacy for immune effector cells using an endpoint of clinical function as approved by the Clinical Program Director Endpoints defined by clinical trial protocols; reported to IND or sponsor Guidance: should be reviewed by clinical director, reported through QM to program Should collect all data elements in the applicable CIBMTR Cellular Therapy forms Define staff responsible for collecting and reporting data to institutional repositories and CIBMTR Reporting is NOT required Standards require annual audit: Accuracy of clinical data on a periodic basis Safety endpoints and immune effector cellular therapy toxicity management annually
24 IMMUNE EFFECTOR CELL ACCREDITATION
25 Why Accreditation for Immune Effector Cells? External validation of quality Assurance to funding organizations and payers Support from general public Regulatory compliance Facilitate peer review Products associated with unexpected, severe adverse reactions, including deaths Accreditation increases preparation, minimize clinical trial set back Various clinical settings; variable QM infrastructure Lack of clarity concerning meaning accreditation for a facility
26 Accreditation Models Blood and marrow transplant (BMT) clinical sites Involvement of BMT physicians = Clinical Program assumes some or all responsibility for IEC therapy No BMT physician involvement = renting out space and sharing nursing resources = optional, shared or separate accreditation Non-transplant clinical sites No limit to amount of resources sharing May be separate or joint with BMT service Immunotherapy divisions or institutes IEC therapy administered across several different clinical sites under same leadership
27 Accreditation Schema Renewal Application 3 months to submit checklist Submit Compliance Application Schedule and Conduct Inspection months to submit checklist Month Determine Outcome and Notify Applicant Correct Deficiencies and Award Accreditation Initial Eligibility Application Note: A delay in any of these steps will require shortened timeframe for subsequent steps. Accreditation is valid for three years.
28 HOW FACT ACCREDITATION SUPPORTS IMMUNE EFFECTOR CELLULAR THERAPY
29 Promoting Patient Safety Controlled processes for procedure development / staff training enhance: Cell collection and processing to protect the integrity and safety of the product Assurance of identity and chain of custody Safe, effective delivery and administration of the cells evaluation of the patient before and after administration Monitoring, self assessments, deviation management detect noncompliance Rapid identification of and response to adverse events imbedded Evaluation and analysis of outcome data Result for individual patients and follow-up care Aggregate data to detect trends and identify improvement opportunities Improved patient outcomes
30 Leveraging HPC Transplant Expertise FACT proven expertise in standards and voluntary accreditation program Experience with drafting minimal standards and applying them to clinical and laboratory sites Knowledge of cell therapy as standard of care can be applied to other specialties Collaboration with experts and professional societies is critical Professional in the field are best suited to set Standards Assess relevance and usefulness of existing standards Determine new / specific Standards FACT IEC Standards collaborations: American Society of Gene & Cell Therapy (ASGCT) Society for Immunotherapy of Cancer (SITC) New therapies to patients requires quality and credibility Early introduction of quality management and process control as addressed in Standards helps avoid pitfalls in clinical trials and speeds products to patients
31 Thank You Resources: Website: Standards, Accreditation Manual, and Quality Handbook: > Store Quality Management Series: Education and Resources > Quality Management Series
Introduction to FACT Immune Effector Cellular Therapy Standards and Accreditation
Introduction to FACT Immune Effector Cellular Therapy Standards and Accreditation Presented by Ngaire Elwood, PhD Vice President, Foundation for the Accreditation of Cellular Therapy (FACT); Director of
More informationCAR T Cell Therapies Workshop
CAR T Cell Therapies Workshop May 15, 2018 Hilton Chicago Continental B Chicago Table of Contents CAR T Cell Therapies Workshop Supporters... p 2 Committee Listing... p 3 Faculty Listing... p 3 Faculty
More informationScope of Practice for the Diagnostic Ultrasound Professional
Scope of Practice for the Diagnostic Ultrasound Professional Copyright 1993-2000 Society of Diagnostic Medical Sonographers, Dallas, Texas USA: All Rights Reserved Worldwide. Organizations which endorse
More informationAccreditation of BMT units & EU Regulations
Accreditation of BMT units & EU Regulations April 1, 2008 EBMT Annual Meeting Workshop: EU regulation/standardisation of cellular therapy Presentation: JACIE: aims and current activities EU regulation
More informationISSUE DATE: 2/10/2006
BULLETIN COMMONWEALTH OF PENNSYLVANIA Department of Public Welfare Department of Health NUMBER: OMHSAS-06-03 ISSUE DATE: 2/10/2006 EFFECTIVE DATE: Immediately SUBJECT: Co-Occurring Disorder Competency
More informationGuidance on the GLP Requirements for Peer Review of Histopathology Advisory Document
GLP Roundtable 2014 Guidance on the GLP Requirements for Peer Review of Histopathology Advisory Document Dr. Elisabeth Klenke, Head Preclinical Review and GLP Monitoring Compliance Unit Swissmedic Swiss
More informationCTO Establishment Inspections. an Atlantic update - Tissues
Transplant Atlantic CTO Establishment Inspections an Atlantic update - Tissues October 14, 2010 Compliance & Enforcement Deliver a national compliance and enforcement program, pursuant of the Food & Drugs
More informationNo Other Company Discloses Higher Transplant Survival Rate. Infusions For Emerging Treatments. Date of Use. Recipient Age (yrs)
Units Used In Transplants/Infusions No Other Company Discloses Higher Transplant Survival Rate Family Banking Provides Exclusive Access To Emerging Treatments With Your Own Cells 175 85% Type 1 Diabetes
More informationTERMS AND CONDITIONS NATIONAL GOOD LABORATORY PRACTICE (GLP) COMPLIANCE MONITORING AUTHORITY
TERMS AND CONDITIONS OF NATIONAL GOOD LABORATORY PRACTICE (GLP) COMPLIANCE MONITORING AUTHORITY FOR OBTAINING AND MAINTAINING ITS GLP CERTIFICATION BY A TEST FACILITY Document No.GLP-101 Version/Issue
More informationNEW MEXICO DEPARTMENT OF HEALTH Administrative Manual ADMINISTRATION
Chapter NEW MEXICO DEPARTMENT OF HEALTH Administrative Manual ADMINISTRATION EFFECTIVE: Policy REVISED: 4/13/9 draft NALOXONE DISTRIBUTION POLICY I. PURPOSE: This New Mexico Department of Health (NMDOH)
More informationInformation Technology Solutions
Information Technology Solutions World Institute of Pain (WIP) Excellence in Pain Practice Award Award Applicant Site Inspection Handbook June 28, 2010 WIP EPP Award Site Inspection Handbook Page 2 Table
More informationUSER INSTRUCTIONS HPC, Cord Blood Donor History Questionnaire. Table of Contents
Page 1 of 9 USER INSTRUCTIONS HPC, Cord Blood Donor History Questionnaire Table of Contents Purpose Introduction Capture Questions Methods of Administration DHQ Materials Structure and Content Reformatting
More informationPOLICIES & PROCEDURES
Policy Name: Page 1 of 7 I. POLICY Evidence-based clinical research regarding influenza has shown that the best method for prevention and control of seasonal influenza is vaccination. The purpose of this
More informationUser Instructions Allogeneic HPC, Apheresis and HPC, Marrow Donor History Questionnaire. Table of Contents
User Instructions Allogeneic HPC, Apheresis and HPC, Marrow Donor History Questionnaire Table of Contents Purpose Introduction Capture Questions Methods of Administration DHQ Materials - Structure and
More informationEnvironmental, Health and Safety
Environmental, Health and Safety Codes of Practice The Environmental, Health and Safety (EHS) Codes of Practice set forth Zimmer EHS requirements for our business functions and facilities worldwide. In
More informationADMINISTRATIVE POLICY AND PROCEDURES MedStar Family Choice Medicare Advantage Plans
ADMINISTRATIVE POLICY AND PROCEDURES MedStar Family Choice Medicare Advantage Plans DEPARTMENT: Medicare Compliance POLICY TITLE: RELATED DEPARTMENTS: All POLICY #: 700C VERSION #: 3 REVISION DATE: Medicare
More informationHEMATOLOGY AND ONCOLOGY
x THE POWER OF HEMATOLOGY AND ONCOLOGY Experts. Experience. Execution. A Deeper Dive into Hematology and Oncology Medpace supports our sponsors who are advancing new anti-cancer therapies by providing
More informationASBMT Fall Clinical Education Conference
The Fred Hutch BMT Program at Seattle Cancer Care Alliance presents The 4th Annual ASBMT Fall Clinical Education Conference Thursday, October 26 Saturday, October 28, 2017 Sheraton Hotel, Seattle, WA Register
More informationNOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.
TITLE INFLUENZA IMMUNIZATION SCOPE Provincial APPROVAL AUTHORITY Vice-President and Chief Health Operations Officer, Central and Southern Alberta SPONSOR Population, Public and Indigenous Health PARENT
More informationUser Instructions Allogeneic HPC, Apheresis and HPC, Marrow Donor History Questionnaire. Table of Contents
User Instructions Allogeneic HPC, Apheresis and HPC, Marrow Donor History Questionnaire Table of Contents Purpose Introduction Methods of Administration DHQ Materials - Structure and Content Reformatting
More informationApril 7, Introduction
April 7, 2017 ICD-10 Coordination and Maintenance Committee Department of Health and Human Services Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, MD 21244-1850 ICDProcedureCodeRequest@cms.hhs.gov
More informationDEVELOPMENTS IN THE CLINICAL TRIALS ENVIRONMENT Two Initiatives February 27, 2014
DEVELOPMENTS IN THE CLINICAL TRIALS ENVIRONMENT Two Initiatives February 27, 2014 Karen Arts, Director Canadian Cancer Clinical Trial Network (3CTN) Chair of the Board of N2 Administrative Office: Lawson
More informationUWMD Workshop: Outcomes and Logic Models. CIG Application Workshop for FY
UWMD Workshop: Outcomes and Logic Models CIG Application Workshop for FY 2012-2013 Overview Outcomes Purpose SMART UWMD Format Examples Logic Models Purpose Everyday Logic Models Tips Construction Evaluation
More information2015 Exam Committees Report for the National Physical Therapy Examination Program
2015 Exam Committees Report for the National Physical Therapy Examination Program Executive Summary This report provides a summary of the National Physical Therapy Examination (NPTE) related activities
More informationKYMRIAH (tisagenlecleucel)
KYMRIAH (tisagenlecleucel) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and
More informationZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015
ZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015 1 Forward-looking Statements This presentation contains certain forward-looking information about ZIOPHARM
More informationThe Practice Standards for Medical Imaging and Radiation Therapy. Sonography Practice Standards
The Practice Standards for Medical Imaging and Radiation Therapy Sonography Practice Standards 2017 American Society of Radiologic Technologists. All rights reserved. Reprinting all or part of this document
More informationRULES OF THE TENNESSEE BOARD OF PHARMACY CHAPTER DRUG DONATION REPOSITORY PROGRAM TABLE OF CONTENTS
RULES OF THE TENNESSEE BOARD OF PHARMACY CHAPTER 1140-17 DRUG DONATION REPOSITORY PROGRAM TABLE OF CONTENTS 1140-17-.01 Definitions 1140-17-.02 Purpose 1140-17-.03 Eligibility Criteria for Program Participation
More informationMODEL JOB DESCRIPTION: ADVANCED SONOGRAPHER
MODEL JOB DESCRIPTION: ADVANCED SONOGRAPHER POSITION SUMMARY The Advanced Sonographer functions as a mid-level healthcare provider who, working under the delegated authority of the supervising physician,
More informationSan Diego Compounding Pharmacy 9/25/17
San Diego Compounding Pharmacy 9/25/17 Division of Pharmaceutical Quality Operations IV 19701 Fairchild Road Los Angeles, CA 92612 WARNING LETTER VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED September
More informationMIAMI CHILDREN S HOSPITAL POLICY AND PROCEDURE
ISSUED BY: Research PAGE: 1 of 6 REPLACES POLICY DATED: EFFECTIVE DATE: 08/09/2012 DISTRIBUTION: Departmentwide APPROVED BY: Andrews, April (SVP/CECO), BOD Audit and Compliance Committee, Perdomo, Jose
More informationPOLICY FRAMEWORK FOR DENTAL HYGIENE EDUCATION IN CANADA The Canadian Dental Hygienists Association
POLICY FRAMEWORK FOR DENTAL HYGIENE EDUCATION IN CANADA 2005 The Canadian Dental Hygienists Association October, 2000 Replaces January, 1998 POLICY FRAMEWORK FOR DENTAL HYGIENE EDUCATION IN CANADA, 2005
More informationYescarta. Yescarta (axicabtagene ciloleucel) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.105 Subject: Yescarta Page: 1 of 5 Last Review Date: September 20, 2018 Yescarta Description Yescarta
More informationSummary of Changes BMT CTN 1101 Version 7.0 to 8.0 Dated: January 18, Original text: Changed to: Rationale
BMT CTN 1101 RIC ducb vs. Haplo Page 1 of 10 Date: January 20, 2017 Summary of Changes BMT CTN 1101 Version 7.0 to 8.0 Dated: January 18, 2017 A Multi-Center, Phase III, Randomized Trial of Reduced Intensity(RIC)
More informationIMMUNE EFFECTOR CELLS: CAR T AND OTHER CYTOTOXIC EFFECTOR CELLS OF THE IMMUNE SYSTEM
IMMUNE EFFECTOR CELLS: CAR T AND OTHER CYTOTOXIC EFFECTOR CELLS OF THE IMMUNE SYSTEM Jennifer Peterson MSN, RN, OCN, BMTCN Jennifer Shamai MS, RN, AOCNS, BMTCN How the Experts Treat Hematologic Malignancies
More informationTRAINING COORDINATOR TRAINING
TRAINING COORDINATOR TRAINING 1. Role of Training Coordinator: Responsible for all sports training for athletes and coaches in the local program. As a sports organization, our main focus should be to assure
More information720 cases. 20 states. Conflict of Interest Declaration. New England Compounding Center (NECC) timeline. (NECC) timeline (continued) 3/28/2013
Conflict of Interest Declaration Compounding at a Crossroads: The Federal and State Outlook Christopher J. Topoleski has no actual or potential conflicts of interest in relation to this activity Christopher
More informationQSEAL Recovered Plasma Specification
QSEAL Recovered Plasma Specification Background The is part of a series of standards that comprise the Plasma Protein Therapeutics Association (PPTA) QSEAL Standards Program. PPTA's Voluntary Standards
More informationGMP IN BLOOD ESTABLISHMENTS: A BASIC ELEMENT FOR PLASMA QUALITY
GMP IN BLOOD ESTABLISHMENTS: A BASIC ELEMENT FOR PLASMA QUALITY Dr. Christian Schärer Swissmedic, Swiss Agency for Therapeutic Products Inspectorates, Hallerstrasse 7 CH-3000 Bern 9 christian.schaerer@swissmedic.ch
More informationNOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.
TITLE PNEUMOCOCCAL IMMUNIZATION SCOPE Provincial APPROVAL AUTHORITY Vice-President and Chief Health Operations Officer, Central and Southern Alberta SPONSOR Population, Public and Indigenous Health PARENT
More informationKymriah. Kymriah (tisagenlecleucel) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.101 Subject: Kymriah Page: 1 of 5 Last Review Date: September 20, 2018 Kymriah Description Kymriah
More informationQuality and Safety of HSCT in Autoimmune Diseases
Quality and Safety of HSCT in Autoimmune Diseases Dr John Snowden Stem Cell Transplant Programme Director Sheffield Teaching Hospitals and University of Sheffield & JACIE Medical Director 1 HSCT is GROWING
More informationExecutive Summary for Executive Licensing Panel 20 May Dr Kamal Ahuja. Follow-up inspection 14 April 2010
Summary for Licensing Panel 20 May 2010 Centre number 0011 Centre name The London Sperm Bank Person Responsible Dr Kamal Ahuja Background Follow-up inspection 14 April 2010 1. The London Sperm Bank underwent
More informationComparability and quality of experimental data under different quality systems. S. Caroli Istituto Superiore di Sanità Rome
Comparability and quality of experimental data under different quality systems S. Caroli Istituto Superiore di Sanità Rome Programme of this presentation Part I. Background information Part II. Key aspects
More informationUnderstanding the U.S. Preventive Services Task Force and its Conflicts of Interest Policies
1 Understanding the U.S. Preventive Services Task Force and its Conflicts of Interest Policies Quyen Ngo-Metzger, MD, MPH Scientific Director, USPSTF Program Agency for Healthcare Research and Quality
More informationCARIBX (UK) LIMITED. Environmental, Health and Safety Management System. Revision: 00 APRIL 2011
CARIBX (UK) LIMITED Environmental, Health and Safety Management System Revision: 00 APRIL 2011 Document Details and Issue Record Rev No. Details Date Author Checked Text 00 Draft 01/04/2011 CJMD Calcs
More informationBMTCN REVIEW COURSE PRE-TRANSPLANT CARE
BMTCN REVIEW COURSE PRE-TRANSPLANT CARE Jennifer Shamai MS, RN, AOCNS, BMTCN Professional Practice Leader Department of Clinical Practice And Professional Education Click How to edit the Master Experts
More informationCommitted to Environment, Health, & Safety
Committed to Environment, Health, & Safety Environment, Health, and Safety Management System and Policy of W. R. Grace & Co. November 8, 2018 The Grace Environment, Health, and Safety Management System,
More informationRO-ILS: Radiation Oncology Incident Learning System Congressional Briefing
RO-ILS: Radiation Oncology Incident Learning System Congressional Briefing Thursday, June 19, 2014, 12:30 p.m. ET Rayburn Building Room B339 Colleen A.F. Lawton, MD, FASTRO Chair, Board of Directors, American
More informationVermont Recovery Network
Vermont Recovery Network 200 Olcott Drive White River Junction, VT 05001 vtrecoverynetwork@gmail.com www.vtrecoverynetwork.org 802-738-8998 The Vermont Recovery Network currently consists of 12 recovery
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Waldenstrom Macroglobulinemia File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem_cell_transplantation_for_waldenstrom_macroglobulinemia
More informationOffice of ENERGY Science
Date: April 29, 2016 U.S. DEPARTMENT OF Office of ENERGY Science SLAC Site Office SLAG National Accelerator Laboratory 2575 Sand Hill Road, MS-.8A Menlo Park, GA 94025 To: Chi Chang Kao, SLAC Laboratory
More informationBlood & Marrow Transplantation Center
Blood & Marrow Transplantation Center We were one of the first centers in the world to routinely offer patients blood and marrow transplantation (BMT). What Sets Us Apart High-volume center performs about
More informationEHR Developer Code of Conduct Frequently Asked Questions
EHR Developer Code of Conduct Frequently Asked Questions General What is the purpose of the EHR Developer Code of Conduct? EHR Association (the Association) members have a long tradition of working with
More informationBOARD OF PHARMACY- REGULATORY UPDATE. Kimberly Grinston, J.D., Executive Director
BOARD OF PHARMACY- REGULATORY UPDATE Kimberly Grinston, J.D., Executive Director Disclosure and Conflict of Interest I declare no conflicts of interest, real or apparent, and no financial interest in any
More informationNational Cancer Peer Review Programme. Radiotherapy Service Evidence Guide
National Cancer Peer Review Programme Radiotherapy Service Evidence Guide Forward This evidence guide has been formulated to assist organisations in preparing for peer review. The contents of this guide
More informationLEGISLATIVE FRAMEWORKS AND ETHICS OF DONATION. Jeff Szer, Royal Melbourne Hospital, Australia
LEGISLATIVE FRAMEWORKS AND ETHICS OF DONATION Jeff Szer, Royal Melbourne Hospital, Australia Donation of HPC Autologous HPC-A HPC-M Allogeneic Family member Volunteer Unrelated HPC-A HPC-M HPC-C Ethical
More informationThe FDA Food Safety Modernization Act: The Key New Requirements
June 15, 2011 The FDA Food Safety Modernization Act: The Key New Requirements Executive Summary INSTITUTE FOR FOOD LAWS & REGULATIONS Michigan State University 140 G.M. Trout Building East Lansing, MI
More informationImplementation of the Stem Cell Therapeutic and Research Act of 2005
Implementation of the Stem Cell Therapeutic and Research Act of 2005 The 6 th Annual Somatic Cell Therapy Symposium Bethesda, MD September 26, 2006 James F. Burdick, M.D. U.S. Department of Health and
More informationDisclaimer. The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be
Ending the Myths: Best Practice in Trial Conduct in Latin America Katie Margules Global Vice President Alliance Management Covance Disclaimer The views and opinions expressed in the following PowerPoint
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_cell_transplantation_for_cll_and_sll 2/2001
More informationNational Institute for Health and Care Excellence. Single Technology Appraisal (STA)
Single Technology Appraisal (STA) Tisagenlecleucel-T for previously treated B-cell acute lymphoblastic Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Please
More informationApproved Care Model for Project 3gi: Integration of Palliative Care into the PCMH Model
1 Approved Care Model for Project 3gi: Integration of Palliative Care into the PCMH Model OneCity Health Webinar January 13, 2016 Overview of presentation 2 Approach to care model development Project overview
More informationIntroduction to EU 'SoHO' Sector Screening Meeting with the Republic of Serbia December 5, 2014 Directorate General for Health and Consumers Unit D4
Introduction to EU 'SoHO' Sector Screening Meeting with the Republic of Serbia December 5, 2014 Directorate General for Unit D4 1. Introduction: SoHO & the Legal Basis 2. The Legislative Framework 3. Blood
More informationLive Educational Programs
Live Educational Programs 2014 Osteoporosis: Essentials of Densitometry, Diagnosis and Management - for Clinicians Osteoporosis: Essentials of Densitometry, Diagnosis and Management - for Technologists
More informationThe Hepatitis C Action Plan for Scotland: Draft Guidelines for Hepatitis C Care Networks
The Hepatitis C Action Plan for Scotland: Draft Guidelines for Hepatitis C Care Networks Royal College of Physicians of Edinburgh Friday 12 October 2007 CONTENTS 1.0 ACCOUNTABILITY AND ORGANISATION 2.0
More informationCARs vs. BiTE in ALL. David L Porter, MD Jodi Fisher Horowitz Professor University of Pennsylvania Health System Abramson Cancer Center
CARs vs. BiTE in ALL David L Porter, MD Jodi Fisher Horowitz Professor University of Pennsylvania Health System Abramson Cancer Center Disclosure Information David L Porter Speaker and members of study
More informationInspections, Compliance, Enforcement, and Criminal Investigations. Central Texas Regional Blood & Tissue Center 07-Nov-03
1 of 7 6/10/2009 2:20 PM Inspections, Compliance, Enforcement, and Criminal Investigations Department of Health and Human Services Public Health Service Food and Drug Administration Dallas District 4040
More informationStandards, Education, Verification. Patient Focused Certification
Standards, Education, Verification Patient Focused Certification PFC Training helps you achieve quality standards. Staff Certification is now available online www.pfctraining.org jahan@safeaccessnow.org
More informationAlcohol & Drug Practice
Alcohol & Drug Practice Vice-President, Health & Safety June 1, 2011 Purpose Cenovus recognizes that the use of alcohol and drugs can adversely affect job performance, the work environment and the safety
More informationDOELAP On-Site Assessment Requirements Checklist Page 1 of 24 Participant:
DOELAP On-Site Assessment Requirements Checklist Page 1 of 24 General Requirements Y, N, N/A Demonstration of Conformance G.1 Latest version of protocols or procedures G.2 Latest version of dosimeter specifications
More informationSeniorMed Education Forum 2008 Piecing Together Today s Senior Healthcare Puzzle. May 1, Tampa Marriott Westshore
SeniorMed Education Forum 2008 Piecing Together Today s Senior Healthcare Puzzle May 1, 2008 - Tampa Marriott Westshore SeniorMed Education Forum is a leading provider of pharmacy products and services
More informationPSP TRAINING CENTRE. Course Calendar
PSP TRAINING CENTRE Course Calendar Fitness and Sports Level 1 (FS1) Fitness and Sports Level 2 (FS2) Fitness and Sports Level 3 (FS3) (Tactical Athlete Instructor) Fitness and Sports Level 4 (FS4) (Assistant
More informationUniversity of Pennsylvania College Houses & Academic Services Graduate Associate Position Description and Contract
University of Pennsylvania College Houses & Academic Services 2017-2018 Graduate Associate Position Description and Contract Staff Member Full Name (print clearly) The Graduate Associate (GA) is a para-professional
More informationSUBJECT: Effective Date: Policy Number: Controlled Substance and Prescription Drugs 11/30/
Division of Research SUBJECT: Effective Date: Controlled Substance and Prescription Drugs 11/30/2018 Supersedes: Page Of 12/04/2015 04/25/2007 1 6 Responsible Authorities: Vice President, Research Institutional
More informationASHE Update HESNI Annual Conference. May 10, 2018
ASHE Update 2018 HESNI Annual Conference May 10, 2018, a professional membership group of the American Hospital Association 155 N. Wacker Drive, Suite 400 Chicago, IL 60606 ashe.org ashe@aha.org 312-422-3800
More informationNANDTB-F012 Rev 0 Audit Checklist
NANDTB-F012 Rev 0 Audit Checklist 1. Foreword Minimum Requirements for the Structured Training of Non-Destructive Testing Institutes This document is based upon CEN Technical Report 25108:2006, which is
More informationSubmitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis
STATEMENT FOR THE RECORD Submitted to the House Energy and Commerce Committee Federal Efforts to Combat the Opioid Crisis October 25, 2017 America s Health Insurance Plans 601 Pennsylvania Avenue, NW Suite
More informationGuideline on the use of minimal residual disease as a clinical endpoint in multiple myeloma studies
1 2 3 26 July 2018 EMA/CHMP/459559/2018 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 Guideline on the use of minimal residual disease as a clinical endpoint in multiple Draft Draft agreed
More informationAABB Standards and Accreditation. Doug Padley, MT (ASCP) Mayo Clinic Rochester MN USA
AABB Standards and Accreditation Doug Padley, MT (ASCP) Mayo Clinic Rochester MN USA Objectives Review AABB standard setting process Describe accreditation program What is AABB? International association
More informationGuidelines on the Sourcing of Medicinal Products for Sale or Supply by a Retail Pharmacy Business
Guidelines on the Sourcing of Medicinal Products for Sale or Supply by a Retail Pharmacy Business to Facilitate Compliance with Regulations 5(1)(g), 6, 8 and 11 of the Regulation of Retail Pharmacy Businesses
More informationSyllabus. The University of Florida College of Pharmacy's Pharmacist Immunization Program contains the following modules:
Syllabus PHARMACIST IMMUNIZATION PROGRAM UNIVERSITY OF FLORIDA COLLEGE OF PHARMACY The University of Florida is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing
More informationPFC Training Courses & Programs. Course Descriptions. 1. Core Cannabis Training (CCT) [pre-requisite for all PFC Courses]
PFC Training Courses & Programs Core Cannabis Training (CCT) National Cannabis Standards Courses (NCST) State Specific Compliance Training (SSCT) PFC Enrichment Courses (PFCEC) PFC Verified Professional
More informationOntario s Narcotics Strategy
Ontario s Narcotics Strategy Ontario Public Drug Programs Ministry of Health and Long-Term Care January 31, 2012 Ontario Harm Reduction Distribution Program Conference 2012 1 Background The Need for Action
More informationAKA Good Manufacturing Practice (GMP) Certification Program
AKA Good Manufacturing Practice (GMP) Certification Program Preamble The American Kratom Association (AKA) is establishing this program to assure the safety and integrity of kratom dietary supplements
More informationa d u lt s t e m c e l l t r a n s p l a n tat i o n p r o g r a m i n f o r m at i o n f o r pay e r s a n d r e f e r r e r s
a d u lt s t e m c e l l t r a n s p l a n tat i o n p r o g r a m i n f o r m at i o n f o r pay e r s a n d r e f e r r e r s Summer 2017 For more information, visit www.dfbwcc.org/bmt. o u r expertise
More informationGood Participatory Practice guidelines
Good Participatory Practice guidelines Prevention Research Advocacy Mentoring and Education Program (PRAMEP) 2 August 2008 Discussion: Is it important to have community representatives participate in the
More informationThe future of HSCT. John Barrett, MD, NHBLI, NIH Bethesda MD
The future of HSCT John Barrett, MD, NHBLI, NIH Bethesda MD Transplants today Current approaches to improve SCT outcome Optimize stem cell dose and source BMT? PBSCT? Adjusting post transplant I/S to minimize
More informationImplementation Guide for the DoseControl Dosimetry System
1.0 SCOPE The GEX DoseControl System is intended for use as a single dosimetry system solution, specifically developed to satisfy the generic dosimetry needs of radiation sterilization application users
More informationWHAT DO MANUFACTURERS AND IMPORTERS HAVE TO DO TO PREPARE FOR EU MEMBERSHIP?
WHAT DO MANUFACTURERS AND IMPORTERS HAVE TO DO TO PREPARE FOR EU MEMBERSHIP? pharmaceutical regulatory affairs consulting and education www.rapharm.eu Vesna Koblar, MD. PhD. EU28: Science, Medicines, Health
More informationOpportunities for Organ Donor Intervention Research
Opportunities for Organ Donor Intervention Research Saving Lives by Improving the Quality and Quantity of Organs for Transplantation Webinar October 19, 2017 Committee Roster Committee on Issues in Organ
More informationBlood & Marrow Transplant Leukemia Immunotherapy
Blood & Marrow Transplant Leukemia Immunotherapy Our Physicians Our specially trained physicians provide leadership for the Northside Hospital Blood and Marrow Transplant, Leukemia and Immunotherapy Programs,
More informationNONE. Disclosures. Accreditation Update
ACR Ultrasound Accreditation: Requirements and Pitfalls Presented to: American Association of Physicists in Medicine Presented by: Jennifer Walter RDMS,RVT, RT(R) ACR Quality & Safety August 03, 2016 Disclosures
More informationGeriatrics / Gerontology Education
2018 Geriatrics / Gerontology Education Call for Proposals Dr. Paula Rochon, RTO/ERO Chair in Geriatric Medicine, with trainees. RTO/ERO Foundation 2018 Grant Criteria & Call for Proposals February 20,
More informationPFC Industry Courses and Certifications
PFC Industry Courses and Certifications Americans for Safe Access (ASA) has been a trusted source of cannabis education and training for over 15 years. As a leader in medical cannabis education since 2002,
More informationHEMATOPOIETIC CELL TRANSPLANTATION FOR EPITHELIAL OVARIAN CARCINOMA
CARCINOMA Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are dependent
More informationEuropean actions in the field of transplantation & blood transfusion
European actions in the field of transplantation & blood transfusion Andrzej Rys Director Directorate Health Systems and Products Madrid, 27 June 2013 1 Blood Tissues and cells Organs 2 Blood transfusion
More information2016 Annual Report. Building An Inclusive Future We Can All Believe In
2016 Annual Report Building An Inclusive Future We Can All Believe In Overview Financial Status Program Highlights Strategic Plan Update Board Governance Mission Statement To ensure individuals with Down
More informationPPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM
HEMATOLOGY ONCOLOGY PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM COMMITTED TO ADVANCING DRUG DEVELOPMENT IN ONCOLOGY $ MARKETPLACE COMPLEXITIES increasingly competitive marketplace and rising cost pressures
More information